воскресенье, 17 января 2016 г.

MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research

MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research


The brokerage presently has a $1.00 target price on the biopharmaceutical company's stock. Zacks Investment Research 's price objective indicates a potential upside of 7.71% from the company's current price.



from Biotech News